Equities researchers at StockNews.com began coverage on shares of Pro-Dex (NASDAQ:PDEX – Get Free Report) in a research note issued to investors on Wednesday. The firm set a “buy” rating on the medical instruments supplier’s stock.
Pro-Dex Price Performance
Shares of PDEX opened at $17.44 on Wednesday. The firm has a market cap of $61.91 million, a price-to-earnings ratio of 13.31 and a beta of 0.88. The stock has a 50 day moving average of $16.46 and a 200-day moving average of $17.26. The company has a current ratio of 3.79, a quick ratio of 1.83 and a debt-to-equity ratio of 0.27. Pro-Dex has a 52 week low of $14.51 and a 52 week high of $19.68.
Pro-Dex (NASDAQ:PDEX – Get Free Report) last posted its quarterly earnings results on Friday, October 13th. The medical instruments supplier reported $0.42 EPS for the quarter. Pro-Dex had a net margin of 6.56% and a return on equity of 10.89%. The business had revenue of $10.64 million during the quarter.
Hedge Funds Weigh In On Pro-Dex
Pro-Dex Company Profile
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
- Five stocks we like better than Pro-Dex
- Growth Stocks: What They Are, Examples and How to Invest
- GSK is a remedy for the winter investment blahs
- How to Invest in Fertilizer
- After blowout earnings, Integer may be headed to new highs
- How to Invest in Apparel Stocks
- Banking and trucking: Is the economy rolling toward troubles?
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.